Real-world Short-term Effectiveness of Ustekinumab in Crohn’s Disease: Results from a Multicenter, Prospective Study in China

Ustekinumab effectively induced a clinical response and clinical remission, with remission rates superior to those in the UNITI-1 study. Ustekinumab is more effective in biologic-naive patients with Crohn’s disease than those who were not responsive to anti–tumor necrosis factor treatment.